MedTrace Logo

A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients

NCT05659602 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2024-10-10

No results posted yet for this study

Summary

To evaluate the preliminary efficacy and safety of HH-120 nasal spray in the treatment of asymptomatic or mild COVID-19.

Conditions

  • Coronavirus Disease 2019(COVID-19)

Interventions

BIOLOGICAL

HH-120 Nasal Spray

HH-120 Nasal Spray 8-10 times per day for 6 consecutive days

Sponsors & Collaborators

  • Beijing Ditan Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-09
Primary Completion
2023-01-03
Completion
2023-01-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05659602 on ClinicalTrials.gov